Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Zevra Therapeutics Q3 EPS $(0.01) Beats $(0.04) Estimate, Sales $26.063M Miss $26.628M Estimate

Author: Benzinga Newsdesk | November 05, 2025 04:14pm
Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.04) by 71.43 percent. This is a 98.55 percent increase over losses of $(0.69) per share from the same period last year. The company reported quarterly sales of $26.063 million which missed the analyst consensus estimate of $26.628 million by 2.12 percent. This is a 605.36 percent increase over sales of $3.695 million the same period last year.

Posted In: ZVRA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist